Centessa Pharmaceuticals (CNTA)

Executive Summary

Centessa Pharmaceuticals is advancing a novel orexin receptor 2 (OX2R) agonist pipeline for sleep-wake disorders, following the termination of several earlier programs (e.g., SerpinPC, LB101) to focus resources on its core asset, ORX750. The company is currently evaluating ORX750 in Phase 2 trials for narcolepsy type 1 and idiopathic hypersomnia, with top-line data expected by mid-2026. Additionally, early-stage programs ORX142 (Phase 1 for excessive daytime sleepiness) and ORX489 (Phase 1 in healthy volunteers) are progressing, providing portfolio breadth. With a market cap of ~$6.1B, the stock is highly dependent on successful proof-of-concept data for ORX750, which could validate the OX2R mechanism and support broader development in neurological and neuropsychiatric indications.

Upcoming Catalysts (preview)

• Q2 2026ORX750 Phase 2 top-line results in narcolepsy type 155% success
• Q2 2026ORX142 Phase 1 safety and pharmacokinetic data readout70% success
• H2 2026ORX489 Phase 1 interim safety data60% success